Supplemental Figure 4 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Year: 2026
Type: supplementary-materials
Abstract: Supplemental Figure 4: Emm55 specific peptides responsible for IgM responses pre and post treatment on individual patients.
Authors: Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik, Zeynep Eroglu, Nikhil I. Khushalani, Christopher W. Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T. Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B. De Aquino, Vernon K. Sondak, Ahmad A. Tarhini, Youngchul Kim, Patricia Lawman, Shari Pilon-Thomas
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7164995200
Cites:
Cited by:
Related to: